Lipid-Lowering Agents - CIS

  • CIS
  • The Lipid-Lowering Agents market in the country of CIS is projected to generate a revenue of US$60.82m in the year 2024.
  • It is expected that the revenue will experience an annual growth rate of -0.42% from 2024 to 2029, resulting in a market volume of US$59.56m by the year 2029.
  • When compared globally, United States is anticipated to generate the highest revenue of US$4,461.00m in 2024.
  • In the CIS market, there is a growing demand for lipid-lowering agents due to the increasing prevalence of cardiovascular diseases and the emphasis on preventive healthcare.

Key regions: Europe, Brazil, France, Australia, Germany

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Lipid-Lowering Agents market in CIS has been experiencing a steady growth in recent years, driven by several factors such as changing lifestyles and increasing awareness of the importance of maintaining healthy cholesterol levels.

Customer preferences:
Customers in CIS have been showing a growing preference for lipid-lowering agents that are more effective, have fewer side effects, and are more affordable. They also prefer agents that are easy to use and come in different forms such as tablets, capsules, and injections.

Trends in the market:
One of the major trends in the Lipid-Lowering Agents market in CIS is the increasing demand for generic drugs. This is due to the fact that generic drugs are more affordable and easily accessible to a wider range of customers. Additionally, there has been a growing trend towards the use of combination therapy, where two or more lipid-lowering agents are used together to achieve better results.

Local special circumstances:
The Lipid-Lowering Agents market in CIS faces some unique challenges such as a lack of awareness among the general population about the importance of maintaining healthy cholesterol levels. Additionally, there are issues with the availability of quality healthcare services in some regions, which makes it difficult for people to access the medication they need.

Underlying macroeconomic factors:
The Lipid-Lowering Agents market in CIS is also influenced by several macroeconomic factors such as the overall economic situation in the region, government policies, and regulatory frameworks. The increasing healthcare expenditure in the region is also expected to drive the growth of the market in the coming years.In conclusion, the Lipid-Lowering Agents market in CIS is expected to continue its steady growth in the coming years, driven by changing customer preferences, the increasing use of generic drugs, and the growing trend towards combination therapy. However, there are still some challenges that need to be addressed such as the lack of awareness among the general population and issues with the availability of quality healthcare services in some regions.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)